Search Results - "LALEZARI, F"

Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers by Trebeschi, S., Drago, S.G., Birkbak, N.J., Kurilova, I., Cǎlin, A.M., Delli Pizzi, A., Lalezari, F., Lambregts, D.M.J., Rohaan, M.W., Parmar, C., Rozeman, E.A., Hartemink, K.J., Swanton, C., Haanen, J B A G, Blank, C.U., Smit, E.F., Beets-Tan, R.G.H., Aerts, H.J.W.L

“…Immunotherapy is regarded as one of the major breakthroughs in cancer treatment. Despite its success, only a subset of patients responds—urging the quest for…”
Get full text

Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experience by Meerveld-Eggink, A., Rozeman, E.A., Lalezari, F., van Thienen, J.V., Haanen, J.B.A.G., Blank, C.U.

“…Combination of T cell checkpoint blockade by CTLA-4- and PD-1-blockade is one of the most promising therapies in patients with advanced melanoma. It induces…”
Get full text

Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics by Schipper, L.J., Samsom, K.G., Snaebjornsson, P., Battaglia, T., Bosch, L.J.W., Lalezari, F., Priestley, P., Shale, C., van den Broek, A.J., Jacobs, N., Roepman, P., van der Hoeven, J.J.M., Steeghs, N., Vollebergh, M.A., Marchetti, S., Cuppen, E., Meijer, G.A., Voest, E.E., Monkhorst, K.

“…In ∼3%-5% of patients with metastatic disease, tumor origin remains unknown despite modern imaging techniques and extensive pathology work-up. With long…”
Get full text

The impact of radiological retroperitoneal lymphadenopathy on survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases by van der Werf, L.R., Wassenaar, E., de Niet, A., Lalezari, F., Braam, H.J., van Ramshorst, B., Nederend, J., de Hingh, I.H.J.T., Kok, N.F.M., Aalbers, A.G.J.

“…To investigate the impact of retroperitoneal lymphadenopathy (RPLP) on pre-operative CT scan on overall survival (OS) and disease-free survival (DFS) after…”
Get full text

Real-World data of patients with synchronous metastatic renal cell carcinoma treated with nivolumab and ipilimumab and the primary tumour in place by Bex, A., Graafland, N., Meerveld-Eggink, A., Wilgenhof, S., Van Thienen, J., Lalezari, F., Grant, M., Szabados, B., Abu-Ghanem, Y., Kuusk, T., Boleti, E., Blank, C., Powles, T., Haanen, J.

Get full text

MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial by Rohaan, M.W., Gomez-Eerland, R., van den Berg, J.H., Geukes Foppen, M.H., van Zon, M., Raud, B., Jedema, I., Scheij, S., de Boer, R., Bakker, N.A.M., van den Broek, D., Pronk, L.M., Grijpink-Ongering, L.G., Sari, A., Kessels, R., van den Haak, M., Mallo, H.A., Karger, M., van de Wiel, B.A., Zuur, C.L., Duinkerken, C.W., Lalezari, F., van Thienen, J.V., Wilgenhof, S., Blank, C.U., Beijnen, J.H., Nuijen, B., Schumacher, T.N., Haanen, J.B.A.G.

“…Adoptive cell therapy with peripheral blood T cells expressing transgenic T-cell receptors (TCRs) is an innovative therapeutic approach for solid malignancies…”
Get full text

A case of abdominal tamponade by SALTZHERR, T. P, LALEZARI, F, GRATAMA, J. W, SPRONK, P. E

Get full text

PO-0994 Registration accuracy of 4D-MRI in lung acquired on the MR-linac by Rossi, M., Fast, M., Van de Lndt, T., Nowee, M., Belderbos, J., Lalezari, F., Sonke, J.

Get full text

Sites of First Progression in the Randomized PET-Boost Trial for Patients With Locally Advanced NSCLC by Cooke, S., de Ruysscher, D., Reymen, B., Lambrecht, M., Persson, G.Fredberg, Faivre-Finn, C., Dieleman, E.M., van Diessen, J., Sikorska, K., Lalezari, F., Sonke, J.J., Belderbos, J.

“…Curative intent conventional chemoradiotherapy for patients with locally advanced NSCLC is typically associated with high progression rates. In the PET-Boost…”
Get full text

18F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): Results from a randomised clinical trial by Cooke, Saskia A., de Ruysscher, Dirk, Reymen, Bart, Lambrecht, Maarten, Fredberg Persson, Gitte, Faivre-Finn, Corinne, Dieleman, Edith M.T., Lewensohn, Rolf, van Diessen, Judi N.A., Sikorska, Karolina, Lalezari, Ferry, Vogel, Wouter, van Elmpt, Wouter, Damen, Eugène M.F., Sonke, Jan-Jakob, Belderbos, José S.A.

“…•Multi-center trial testing two personalised radiotherapy dose-escalation strategies.•107 patients with stage II/III disease and a large primary tumour were…”
Get full text

1133P Whole genome sequencing can classify diagnostically challenging tumors by Schipper, L.J., Snaebjornsson, P., Samsom, K.G., Bosch, L.J.W., Lalezari, F., Priestley, P., Shale, C., Jacobs, N., van den Broek, A.J., Roepman, P., van der Hoeven, J.J.M., Steeghs, N., Cuppen, E., Meijer, G., Voest, E.E., Monkhorst, K.

Get full text

LBA3 Treatment with tumor-infiltrating lymphocytes (TIL) versus ipilimumab for advanced melanoma: Results from a multicenter, randomized phase III trial by Haanen, J.B.A.G., Rohaan, M., Borch, T.H., van den Berg, J.H., Met, Ö., Foppen, M. Geukes, Granhøj, J. Stoltenborg, Nuijen, B., Nijenhuis, C., Beijnen, J.H., Jedema, I., van Zon, M., Noringriis, I. Mansfield, Kessels, R., Wilgenhof, S., van Thienen, H.V., Lalezari, F., van Akkooi, A.C.J., Donia, M., Svane, I-M.

Get full text

OC-0609: The PET-boost trial: isotoxic homogeneous or FDG-directed dose escalation in stage II-III NSCLC by Cooke, S., De Ruysscher, D., Reymen, B., Lambrecht, M., Persson, G. Fredberg, Faivre-Finn, C., Dieleman, E., Lewensohn, R., Van Diessen, J., Sikorska, K., Lalezari, F., Sonke, J., Belderbos, J.

Get full text

OC-0692: Phase 1 study of olaparib as radiosensitizer for locally advanced non-small cell lung cancer by De Haan, R., Van Diessen, J., Peulen, H.M.U., Van Werkhoven, E., De Langen, A.J., Lalezari, F., Vens, C., Schellens, J., Steeghs, N., Van Den Heuvel, M.M., Verheij, M., Van Triest, B.

Get full text

The prognostic value of respiratory symptoms and performance status in ambulatory cancer patients and unsuspected pulmonary embolism; analysis of an international, prospective, observational cohort study by Maraveyas, Anthony, Kraaijpoel, Noémie, Bozas, George, Huang, Chao, Mahé, Isabelle, Bertoletti, Laurent, Bartels‐Rutten, Annemarieke, Beyer‐Westendorf, Jan, Constans, Joel, Iosub, Diana, Couturaud, Francis, Muñoz, Andres J., Biosca, Mercedes, Lerede, Teresa, van Es, Nick, Di Nisio, Marcello

“…Background Optimal risk stratification of unsuspected pulmonary embolism (UPE) in ambulatory cancer patients (ACPs) remains unclear. Existing clinical…”
Get full text

Gross tumour volume (GTV) delineation on magnetic resonance imaging (MRI), for stage III lung cancer: consensus recommendations needed to ensure contouring consistency by Shiarli, A., Brown, S., Dubec, M., Bainbridge, H., Koh, D., Lalezari, F., Van Herk, M., Wetscherek, A., Knowles, E., Faivre-Finn, C., Mcdonald, F.

Get full text

EP-1346 A framework for systematic clinical evaluation of the MR-linac for treatment of lung cancer patients by Cobben, D., Bainbridge, H., Belderbos, J., Cheung, P., Dubec, M., Gomez, D., Gore, E., Knowles, E., Lalezari, F., Oelfke, U., Sonke, J., Tijssen, R., Van Es, C., Van Herk, M., Wetscherek, A., McDonald, F., Faivre-Finn, C.

Get full text

LBA92 - Switch maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma: A multicenter open label phase II trial (NVALT19) by Burgers, S.A., de Gooijer, C., Cornelissen, R., Aerts, J.G., Biesma, B., Heemst, R.V., Youssef-El Soud, M., Groen, H.J.M., Staal-van den Brekel, A.J., Bootsma, G., Schijen, J H E M, Baas, P., Giovannetti, E., de Vries, J.F., Hogenboom, F.A., de Wit, D.C.M., Mahn- Schaefers, M.C.W., Lalezari, F., van de Noort, V., Stigt, J.

“…All malignant mesothelioma (MM) patients progress after first-line therapy. We examined whether switch maintenance gemcitabine in patients, who did not show…”
Get full text

Results of a phase I trial with MART-1 T cell receptor modified T cells in patients with metastatic melanoma by Rohaan, M.W., Gomez-Eerland, R., Foppen, M H Geukes, van Zon, M., de Boer, R., Bakker, N.A.M., Pronk, L.M., Sari, A., Mallo, H.A., van de Wiel, B.A., Lalezari, F., Beijnen, J.H., Nuijen, B., van Tinteren, H., van Thienen, J.V., Blank, C.U., Wilgenhof, S., Schumacher, T.N., van den Berg, J.H., Haanen, J B A G

Get full text

1184PD - Results of a phase I trial with MART-1 T cell receptor modified T cells in patients with metastatic melanoma by Rohaan, M.W., Gomez-Eerland, R., Foppen, M H Geukes, van Zon, M., de Boer, R., Bakker, N.A.M., Pronk, L.M., Sari, A., Mallo, H.A., van de Wiel, B.A., Lalezari, F., Beijnen, J.H., Nuijen, B., van Tinteren, H., van Thienen, J.V., Blank, C.U., Wilgenhof, S., Schumacher, T.N., van den Berg, J.H., Haanen, J B A G

“…Adoptive cell therapy (ACT) with T cell receptor (TCR) gene modified peripheral blood T cells creates large pools of tumor reactive T cells. Based on…”
Get full text